Amgen (AMGN): FY26 Q1 earnings call, Apr 30, 2026
No Kalshi or Polymarket word markets were listed for Amgen’s Apr 30, 2026 earnings call (FY26 Q1). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
3 matches for “Patent”; 3 quoted, at least 25 words apart.
…we expect our rapidly growing products to offset the financial impact of patent expirations and increased competition, while our next generation of molecules progress through…
…once again to demonstrate that we can grow through a period of patent expiration and deliver attractive performance for our shareholders with a strong portfolio…
…our strong first quarter performance, executing through a full quarter of the patent expirations and losses of exclusivity. Our non-GAAP operating margin was 45%. We…
Agents: this page as TSV at /api/v1/appearances/amgen:2026-04-30:earnings_call · words: /api/v1/brief?appearance=amgen:2026-04-30:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP